Vera Therapeutics’ (VERA) Neutral Rating Reiterated at Wedbush

Wedbush reaffirmed their neutral rating on shares of Vera Therapeutics (NASDAQ:VERA) in a research note published on Monday,Benzinga reports. They currently have a $34.00 price target on the stock.

Other equities research analysts also recently issued research reports about the company. Bank of America upped their target price on Vera Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Guggenheim raised their target price on Vera Therapeutics from $56.00 to $76.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. William Blair reissued an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Evercore set a $91.00 price target on Vera Therapeutics in a report on Friday, May 15th. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $84.00 price target on shares of Vera Therapeutics in a report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Vera Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $81.15.

Vera Therapeutics Stock Performance

Shares of VERA stock opened at $32.28 on Monday. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.18. The company has a market cap of $2.33 billion, a PE ratio of -5.51 and a beta of 0.92. The company’s fifty day simple moving average is $36.40 and its 200-day simple moving average is $38.16. Vera Therapeutics has a 52 week low of $21.15 and a 52 week high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.58) by $0.06. During the same quarter in the previous year, the firm earned ($1.20) EPS. As a group, equities research analysts anticipate that Vera Therapeutics will post -6.43 EPS for the current year.

Insider Activity

In related news, CEO Marshall Fordyce sold 46,250 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total value of $1,956,375.00. Following the sale, the chief executive officer directly owned 151,994 shares of the company’s stock, valued at $6,429,346.20. This represents a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 15.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in VERA. E. Ohman J or Asset Management AB increased its position in shares of Vera Therapeutics by 99.5% in the 2nd quarter. E. Ohman J or Asset Management AB now owns 85,777 shares of the company’s stock worth $3,681,000 after purchasing an additional 42,787 shares during the last quarter. Handelsbanken Fonder AB lifted its position in shares of Vera Therapeutics by 11.6% during the second quarter. Handelsbanken Fonder AB now owns 22,100 shares of the company’s stock worth $948,000 after purchasing an additional 2,300 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Vera Therapeutics by 26.7% during the first quarter. Janus Henderson Group PLC now owns 17,658 shares of the company’s stock worth $710,000 after purchasing an additional 3,723 shares during the last quarter. ADAR1 Capital Management LLC grew its stake in Vera Therapeutics by 8.8% in the first quarter. ADAR1 Capital Management LLC now owns 16,033 shares of the company’s stock worth $645,000 after purchasing an additional 1,300 shares in the last quarter. Finally, California State Teachers Retirement System grew its stake in Vera Therapeutics by 31.5% in the first quarter. California State Teachers Retirement System now owns 49,737 shares of the company’s stock worth $2,001,000 after purchasing an additional 11,907 shares in the last quarter. 99.21% of the stock is owned by institutional investors and hedge funds.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.